🎉 Free to use until Sep 16, 2026 — try it out for our launch!
STOCKIQAISTOCKIQAI
עברית
S&P 5007,709.96▼ 0.18%
Dow Jones53,885.1▼ 0.85%
Nasdaq26,348.35▼ 0.06%
Russell 20003,001.55▼ 0.58%
Fear Index (VIX)15.31▲ 1.06%
TA-125₪4,050.45▲ 0.45%
S&P 5007,709.96▼ 0.18%
Dow Jones53,885.1▼ 0.85%
Nasdaq26,348.35▼ 0.06%
Russell 20003,001.55▼ 0.58%
Fear Index (VIX)15.31▲ 1.06%
TA-125₪4,050.45▲ 0.45%

STOK

Stoke Therapeutics Inc. Common Stock

Health Care · ·

$31.93

▼ $0.00 (-0.0%)

Market Cap

$2.06B

Day Range

$31.63 - $33.09

52-Week Range

$12.86 - $40.22

Beta

—

Next Earnings

—

STOK is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.

🏢 Similar Stocks in the Same Sector

AAPG

Ascentage Pharma Group International - American Depository

AARD

Aardvark Therapeutics, Inc.

ABCL

AbCellera Biologics Inc. - Common

+142.4% (1Y)

Investor Score
58/ 100C
🟡 Moderate

This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer

📈78B+Technical
💰25FFundamental
🚀82A-Growth
💎38FValuation
📰74BNews
🏦58CQuality
⚠️48D+Risk

Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%

🔍 Cross-Check

Overall Score

🟡 Mixed

Technical Trend

🟢 Bullish

Insiders

🔴 Bearish

✅ Why is the score relatively high?

  • 🟢 Revenue growth (last year): 404.5%
  • 🟢 Earnings per share (EPS) growth: 92.7%
  • 🟢 Free cash flow growth: 151.6%
  • 🟢 Net income growth: 92.3%
  • 🟢 Operating margin is stable or improving over time

⚠️ What's concerning?

  • 🔴 Estimated fair value: $19.35 vs. price $31.93 (-39.4%)
  • 🔴 Operating margin: -11.2% (negative)
  • 🔴 Net margin: -3.7% (negative)
  • 🔴 ATR: 5.3% of price
  • 🔴 Return on equity (ROE): -2.0% (negative)

🚦 Quality & Risk Checks

🟢 Operating margin stability🔴 Daily volatility (ATR)🟢 Liquidity risk

📰 News Trend

Based on real financial news (Finnhub)
🟢 Positive

Everyone's writing about Stoke Therapeutics Inc. Common Stock. News trend score: 74. Reason: 5 of the last 11 articles are positive, versus 1 negative.

🟡 What Is Stoke Therapeutics (STOK) Signaling With A 2 Million Share Shelf Filing? — Simply Wall St.🟢 Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference — Business Wire🟡 Stoke Therapeutics, Inc. Q2 2026 Earnings Call Summary — Moby

News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer

📈 Technical Analysis

Based on the last 251 trading days, calculated from real price data. Click an indicator for details and a chart.

🟢 Most indicators support an uptrend (9 bullish · 2 bearish · 1 neutral)

Conclusions

  • 🟢Price vs. SMA 50 — Price is above the 50-day average
  • 🟢Price vs. SMA 200 — Price is above the 200-day average
  • 🟢MACD — MACD histogram is positive — rising momentum
  • 🟢RSI — RSI 60.0 — healthy positive momentum
  • 🔴Stochastic — %K 81.6 — overbought
  • 🟡ADX (trend strength) — ADX 19.0 — weak trend/choppy
  • 🟢Volume trend — Rising volume supports the price advance
  • 🔴Relative strength vs. S&P 500 — -7.9% over the last 3 months relative to the index
  • 🟢Bollinger Bands — Price is in the upper third of the Bollinger Bands (95%B) — strong momentum (risk of a pullback)
  • 🟢ROC (rate of change) — ROC 12 days: 15.4%
  • 🟢Parabolic SAR — Price is above the SAR point — uptrend
  • 🟢CMF (money flow) — CMF 20 days: 0.20

Wyckoff Method Analysis

A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.

Accumulation

A trading range after a decline, but still without clear (volume-based) confirmation of an accumulation phase.

Low confidence

$27.24

Range Bottom

$33.72

Range Top

50

Trading Days in Range

Evidence Behind This Read

  • 🟡Trading range identified — The stock is trading in a 23.8% range (between 27.24 and 33.72) over 50 trading days.
  • 🟢The range follows a downtrend — Under the Wyckoff method, a trading range following a decline is a natural candidate for an Accumulation phase — smart money buying from weak sellers.
  • 🟡Trading volume in the range is rising — There's no clear sign yet of supply/demand being exhausted within the range.

The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.

🎯 Trade Planning (M.A.E.E Framework)

Based on a mechanical trading method: market structure → value zone → ATR-based exit point. Not investment advice — a calculation tool only.

1️⃣ Market Structure

🟡 Range

The price is oscillating around the 200-day average with no clear direction — the method recommends great caution here (buying at the bottom of the range / selling at the top) or avoiding trading altogether.

2️⃣ Value Zone

🟡 Price far from value zone

The price is currently far from the 50-day average — the method recommends waiting for a "pullback" before entering, rather than chasing prices.

In a range, the method doesn't give a single directional stop point — the market currently lacks a clear direction, consider waiting for a breakout from the range.

💰 Financial Health

Profitability

Gross Margin

—

Operating Margin

-11.2%

Net Margin

-3.7%

EBITDA Margin

-11.2%

Efficiency

ROE

-2.0%

ROA

-1.6%

ROIC

—

EPS

-$0.12

Balance Sheet

Cash

$84.22M

Total Debt

—

Current Ratio

5.28

Debt/Equity

—

Conclusions

  • 🔴Operating margin — Operating margin: -11.2% (negative)
  • 🔴Net margin — Net margin: -3.7% (negative)
  • 🔴Return on equity (ROE) — Return on equity (ROE): -2.0% (negative)
  • 🔴Return on assets (ROA) — Return on assets (ROA): -1.6% — weak
  • 🟢Current ratio (liquidity) — Current ratio: 5.28
  • 🔴Interest coverage — Interest coverage: -2287.8x

🚀 Growth

Revenue

Earnings per Share (EPS)

Net Income

Free Cash Flow (FCF)

Conclusions

  • 🟢Revenue growth (last year) — Revenue growth (last year): 404.5%
  • 🟢Earnings per share (EPS) growth — Earnings per share (EPS) growth: 92.7%
  • 🟢Free cash flow growth — Free cash flow growth: 151.6%
  • 🟢Net income growth — Net income growth: 92.3%

💎 Fair Value (Valuation)

Current Price

$31.93

Estimated Fair Value (DCF)

$19.35

Gap

-39.4%

🔴 Appears expensive relative to estimated value

Show all model (DCF) assumptions →

Year 1 Growth Rate

25.0%

Discount Rate (WACC)

9.0%

Terminal Growth Rate

2.5%

Projection Years

5

YearGrowth RateProjected FCFPresent Value
125.0%$56.14M$51.51M
219.4%$67.02M$56.41M
313.8%$76.24M$58.87M
48.1%$82.43M$58.40M
52.5%$84.49M$54.91M

Base FCF (last actual year)

$44.91M

Terminal Value

$1.33B

Present Value of Terminal Value

$865.95M

Enterprise Value

$1.15B

Net Debt

$0

Equity Value

$1.15B

*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.

Book Value per Share

$5.95

Tangible Book Value per Share (Tangible NAV)

$5.95

Conclusions

  • 🔴DCF Fair Value — Estimated fair value: $19.35 vs. price $31.93 (-39.4%)
  • 🟡Tangible Net Asset Value (NAV) — NAV per share: $5.95
  • 🟡P/E — P/E: -266.1

🕴️ Insider Trading

Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 5 sales out of the last 25 filings.

NameTransaction TypeDateSharesChangePrice
Ticho BarryOpen Market Sale3.8.20261,269-1,269$29.45
Ticho BarryOpen Market Sale3.8.20265,907-5,907$28.95
Harrison Seth LoringGift16.7.202617,786+17,786—
Harrison Seth LoringGift16.7.202617,786-17,786—
Harrison Seth LoringGift16.7.202629,747+29,747—
Harrison Seth LoringGift16.7.202629,747-29,747—
Harrison Seth LoringGift16.7.20267,639+7,639—
Harrison Seth LoringGift16.7.20267,639-7,639—
Harrison Seth LoringGift16.7.202619,441+19,441—
Harrison Seth LoringGift16.7.202619,441-19,441—
Harrison Seth LoringGift16.7.202621,000+21,000—
Harrison Seth LoringGift16.7.202621,000-21,000—
Harrison Seth LoringGift16.7.202611,650+11,650—
Harrison Seth LoringGift16.7.202611,650-11,650—
Harrison Seth LoringGift16.7.202614,777+14,777—
Harrison Seth LoringGift16.7.202614,777-14,777—
Harrison Seth LoringGift16.7.202629,555+29,555—
Harrison Seth LoringGift16.7.202629,555-29,555—
McCauley ThomasGrant/Award from Employer15.7.2026225,000+225,000—
Ticho BarryOpen Market Sale1.7.2026500-500$33.27
Ticho BarryOpen Market Sale1.7.20266,728-6,728$32.62
Allan JonathanOpen Market Sale16.6.20261,457-1,457$29.95
Burstein JenniferGrant/Award from Employer3.6.202617,786+17,786—
Harrison Seth LoringGrant/Award from Employer3.6.202617,786+17,786—
Kaye Edward M. MDGrant/Award from Employer3.6.202617,786+17,786—

📉 Short Interest

Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.

Monthly Trend — Open Short Interest

↑+12.8%

15,692,610 shares short as of 2026-07-15 · vs. 13,908,522 on 2026-06-30

Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.

Weekly Trend — Daily Short-Sale Activity

↓-11.0%

52.6% of trading volume this week was short selling, vs. 59.1% the prior week

Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.

📰 News & Sentiment

Sentiment based on basic keywords (not AI) — 5 positive, 5 neutral, 1 negative out of the last 11 articles.